Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
Sara Raponi(Sapienza University of Rome), Robin Foà(Sapienza University of Rome), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Massimo Gentile(Azienda Ospedaliera di Cosenza), Francesca Romana Mauro(Sapienza University of Rome), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Vincenzo Cappelli(Cornell University), Ilaria Del Giudice(Sapienza University of Rome), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alfonso Piciocchi(Fondazione Gimema Onlus), Chiara Favini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luciana Cafforio(Center for Genomic Science), Irene Della Starza(Associazione Italiana Ematologia Oncologia Pediatrica), Paola Mariglia(Sapienza University of Rome), Anna Guarini(Sapienza University of Rome), Valentina Arena(Fondazione Gimema Onlus), Caterina Ilari(Sapienza University of Rome), Giovanna Cutrona(Ospedale Policlinico San Martino)
Cited by 23
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378